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of FOXM1 (Gartel, 2010, 2012). According 
to this model, siomycin A, thiostrepton, 
and other proteasome inhibitors hinder 
the proteasomal degradation of a nega-
tive regulator of FOXM1 (NRFM), which 
in return directly or indirectly inhibits the 
activity of FOXM1 as a transcription factor 
(Gartel, 2011). Because FOXM1 is involved 
in a positive feedback loop and activates 
its own transcription (Halasi and Gartel, 
2009), inhibition of FOXM1 transcriptional 
activity leads to a decrease in its expression 
(Gartel, 2010). This model also anticipates 
that all proteasome inhibitors regardless of 
their structure will inhibit FOXM1 tran-
scriptional activity through stabilizing the 
NRFM and subsequently (via the auto-reg-
ulatory loop) inhibit FOXM1 expression 
(Gartel, 2011, 2012). Overall, inhibition of 
FOXM1 transcriptional activity by siomy-
cin A, thiostrepton, and other proteasome 
inhibitors is an essential part of their regula-
tion of FOXM1.
FOXM1 is without a doubt emerging as 
a critical regulator of cancer development 
(Halasi and Gartel, 2013) that may affect 
all hallmarks of cancer (Hanahan and 
Weinberg, 2012). Originally, it was identified 
as a key regulator of cell proliferation and 
cell cycle progression; however, in the past 
few years FOXM1 became one of the cen-
tral contributors to tumorigenesis. Growing 
body of evidence suggests that targeting this 
single transcription factor may have great 
promise for inhibiting tumor development. 
Great efforts are currently being undertaken 
to find more specific inhibitors of FOXM1 
and to elucidate their mechanism of action. 
I believe it is essential for the scientific com-
munity to have correct information about 
the regulation of FOXM1 by FOXM1 inhibi-
tors in order to progress and accelerate 
research in the FOXM1 field.
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I read with great interest the review article 
by Alvarez-Fernández and Medema (2013). I 
was especially pleased to see that the authors 
comprehensively acknowledged our work by 
citing six of our recent papers in their review. 
However, when they discussed our findings 
on the identification of the thiazole antibiot-
ics siomycin A and thiostrepton as inhibitors 
of FOXM1 transcriptional activity they made 
a significant mistake. They wrongly stated, 
“surprisingly, these inhibitors do not affect 
the transcriptional activity of FOXM1 per 
se.” In numerous publications we showed 
that indeed siomycin A and thiostrepton 
inhibit the transcriptional activity and the 
expression of FOXM1, and they also act 
as proteasome inhibitors (Radhakrishnan 
et al., 2006; Bhat et al., 2009a,b). Moreover, 
we demonstrated that even in the presence of 
high levels of exogenous FOXM1 siomycin A, 
thiostrepton, and known proteasome inhibi-
tors were able to inhibit FOXM1 transcrip-
tional activity, suggesting that this inhibition 
is a key initiating event for FOXM1 protein 
suppression (Radhakrishnan et al., 2006; 
Bhat et al., 2009a,b).
In addition, the authors concluded that 
both the mRNA and protein expression of 
FOXM1 are downregulated by siomycin 
A and thiostrepton “through an unknown 
mechanism” (Alvarez-Fernández and 
Medema, 2013). However, recently I have 
proposed a general model for FOXM1 inhi-
bition by proteasome inhibitors, which links 
the transcriptional activity and expression 
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